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Abstract 
Background: Nonalcoholic fatty liver disease (NAFLD) is an important cause of liver 
diseases. Gastrointestinal microbiota dysbiosis elicits and aggravates NAFLD into 
Non-Alcoholic Steatohepatitis (NASH) and cirrhosis, increasing morbidity and 
mortality. Microbial manipulation such as probiotic supplementation has been found 
to treat NAFLD and prevent reverse its progression. However, the study about the 
protective effect of probiotics on NAFLD is still limited.  
Objective: This study aimed to evaluate the effect of probiotics on liver histopathology 
Sprague-Dawley rats which given a High-Fat-High-Fructose (HFHFr) diet 
Methods: This study was a post-test-only control study group design. The samples 
were 21 Sprague-Dawley male rats in 7 – 8 weeks of age and were divided into three 
groups.The Control Group (C) was provided with a standard chow diet. The Non-
Probiotic (NP) group was given a HFHFr diet for eight weeks. The Probiotic group (P) 
was given a HFHFr diet for eight weeks, and a combination of HFHFr and probiotic 
consisted of Lactobacillus acidophilus, Bifidobacterium longum, and Streptococcus 
thermophilus for the next eight weeks. Histopathological samples were obtained from 
liver biopsy to assess NAFLD activity score (NAS), and fibrosis stages. We analyzed 
the difference in histopathological results using the Fisher’s Exact Test. 
Results: We found a significant difference in NAFL and NAS Score between NP and 
P group. The P group was shown to have lower trends for NAFLD and NASH than the 
NP group, but not for fibrosis.  
Conclusion: Probiotics supplementation reduced steatosis and inflammation of the 
liver 
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INTRODUCTION 
 Non-alcoholic fatty liver disease (NAFLD) has 
emerged as one of the most common chronic liver 
diseases in the paediatric population.1 In patients with 
NAFLD, 16 % will develop advanced fibrosis, and 9.3% 
developing end-stage liver disease2. Non-Alcoholic 
Fatty Liver Disease (NAFLD) is a group of disorders 
characterized by macrovesicular hepatic steatosis, 
fibrosis, and end-stage liver disease and occurs in 
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 Several risk factors are associated with induction and 
development of NAFLD and Nonalcoholic 
Steatohepatitis (NASH), such as type 2 diabetes mellitus, 
dyslipidemia, and metabolic syndrome. Diets associated 
with those conditions including High-Fat-High-Fructose 
diet, will also affect liver function and development into 
NAFLD or NASH. High concentration of sugar and fat 
induces hepatic de novo lipogenesis. This type of diet 
also gives rise for endoplasmic reticulum stress, 
promoting mitochondrial dysfunction and elevating 
hepatocytes apoptosis. 4, 5 
 Alterations in gut microbiota composition and 
function negatively impacts the host (dysbiosis) and play 
causal roles in developing NAFLD.6 As the liver receives 
major blood supply from the intestine, it has a particular 
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Dysbiosis caused endotoxins and toxic metabolite 
production that compromised intestinal permeability, 
increasing the entry of bacterial metabolites and 
components into the liver through the portal vein.7 The 
microbiota can aggravate NAFLD through various 
mechanisms, one of them is by influencing short-chain 
FAs (SCFAs) synthesis and lipogenesis, increasing liver 
fat deposition and resulting in steatosis.8 In a study in 
which gut microbiota collected from obese donors were 
transplanted into germ-free mice, the mice that received 
gut microbiota before donor’s weight loss had higher 
levels of hepatic triglyceride and cholesterol than mice 
that received post-weight loss gut microbiota.6 This 
mechanism, combined with inflammation caused by 
toxic microbiota product (especially 
lipopolysaccharide), will damage the liver, progressing 
into NASH, cirrhosis, or even hepatocellular 
carcinoma.9 
 Specific measures to “balance” the intestinal 
microbiota to its normal state are widely studied.10 
Studies showed the gut microbiota has a crucial role in 
the pathogenesis of NASH/NAFLD, support the 
hypothesis that microbiota manipulation is a potential 
and effective therapy as an alternative in the 
management of NAFLD/NASH.10 Probiotics, by WHO, 
are defined as live microorganisms which when 
administered in adequate amounts.11 In several 
experiments with murine models, probiotic 
supplementation improved liver histology, reduced liver 
fat, decreased serum ALT, and reduced liver fibrosis.9  
However, there was still limited data regarding the 
hepatoprotective effect of probiotic supplementation. 
 This study aims to determine the probiotic’s role as 
protective agents against NAFLD and NASH in murine-
models. 
 
MATERIALS AND METHODS  
 We performed a murine-model post-test only control 
study group design conducted in Animal Experimental 
Laboratory in Faculty of Medicine Airlangga University, 
Surabaya, Indonesia. Bodyweight and the length of all 
rats were measured before the experiment. The samples 
were 21 Sprague-Dawley male rats at 7 – 8 weeks of age. 
After one week of acclimatization, we divided those 
samples into three groups. The Control Group (C) was 
provided with a standard chow diet for eight weeks. The 
Non-Probiotic (NP) group was given High-Fat-High-
Fructose (HFHFr) diet for eight weeks. The Probiotic 
group (P) was given HFHFr diet for eight weeks, and a 
combination of HFHFr and probiotic supplementation 
consisted of Lactobacillus acidophilus, Bifidobacterium 
longum, and Streptococcus thermophilus for the next 
eight weeks. HFHFr diet consists of 59% of energy 
derived from fat, 30% from carbohydrates, and 11% 
from protein, and standard chow diet with 10% of energy 
derived from fat, 30% from protein, and 60% from 
carbohydrates.12 
 After treatment, all the rats were measured for post-
test body weight and sacrificed. Histopathological 
samples were obtained from liver biopsy. We made 4μm 
slides of liver tissue and then stained them with routine 
hematoxylin-eosin and Masson stain to see the fibrosis. 
According to Kleiner etal., histopathological 
examination for assessing NAFLD Activity Score 
(NAS) is comprised of steatosis, lobular inflammation, 
cellular ballooning, and fibrosis. (see table 1) We further 
evaluate the non-alcoholic fatty liver status by using the 
5% steatosis as a cut-off point. NAFLD is defined by the 
presence of steatosis in >5% of hepatocytes, using only 
the ‘steatosis grade’ component of NAS. We also 
evaluate the NAS Score into three categories: Not NASH 
(Score 1 – 2), Borderline (Score 3 – 4), and NASH (Score 
5 – 8). We also categorized the fibrosis stage using 
Kleiner score criteria.13  
 We presented the data in mean and standard 
deviation. Histopathological data is shown in cross-
tabulation. Statistical analysis was carried out using the 
IBM SPSS Statistics 25.0 statistical program. We 
measured the difference in histopathological results using 
the Mann-Whitney test. Significant difference marked 
with p-value less than 0.05 
 This study protocol was approved by Ethical 
Committee of Faculty of Medicine, Universitas 




 In this study, 21 rats were intervened and analyzed for 
histopathological analysis. Anthropometric 
measurements were shown in table 1. We found no 
significant difference between pre-test and post-test body 
weight. (p > 0.05) (see table 2) 
 Our histopathology results (see figure 1) were 
presented in cross-tabulation. Our control group did not 
develop NAFLD and NASH, although rats in those 
groups developed stage I fibrosis. We also found that in 
the probiotic group, there were fewer subjects developing 
NAFLD (see table 3), NASH (see table 4), and stage II 
fibrosis (see table 5) 
 Fisher’s Exact analysis showed that compared to the 
NP group, the P group was shown to have lower trends 
for NAFLD (p = 0.001) and NASH (p = 0.001). It is 
shown that the P group had a lower trend for the fibrosis 
stage, although not statistically significant. (p = 0.500) 
 
DISCUSSION 
 In present study we found that 8 weeks of HFHFr diet 
was already able to induce NAFL in our NP group. This 
finding was in parallel with a German murine-model 
study that found 8 weeks of HFHFr diet increased hepatic 
fat deposition. The same study also discovered altered 
intestinal barrier function in mice given the diet.14 A 
study in China found that high-fat diet induced dysbiosis 
in gastrointestinal microbiota and significantly increased 
the risk of metabolic syndrome, as shown by increased 
body weight, decreased insulin sensitivity, and marked 
dyslipidemia.15 It was supported by the fact that in 
dysbiosis, the altered gut microbiota used choline for 
metabolism, reducing free choline and inhibiting very-
low-density lipoprotein (VLDL) excretion from the liver. 
Combined with increased intake of fat, especially short-
chained fatty acid, excessive fat deposition was 
inevitable.16 We hypothesized that the HFHFr diet in our 
study was able to induce dysbiosis . We found no rats in 
P group had steatosis at the end of our treatment. This 
finding supported the fact that in this study, probiotic 
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result was in line with several studies, as probiotic 
supplementation showed a significant decrease in 
NAFLD scores, steatosis, and improvement in the liver 
enzyme.17, 18   
 We found that eight weeks of probiotics 
supplementation significantly reduce the NAS Score 
criteria (from NASH to Borderline) on all rats in the P 
group. This finding was in line with a previous study that 
significantly reduced inflammatory markers and 
steatosis following probiotic supplementation.19 
Interestingly, despite the non-NAFLD status of all the P 
group rats, the liver histology is still classified with 
borderline, signifying some degree of inflammation. The 
key factors that play a role in converting mild fatty liver 
to NASH have not yet been determined. Some key 
factors include oxidative stress, lipid peroxidase, 
reactive metabolites, adipose tissue products, and gut 
microbiota dysbiosis.20 These evidence were supported 
by a clinical trial in NASH patients treated with 
antibiotics. The patients’ NASH degree were 
significantly lowered followed by microbiota change 
detected in stools.21 We hypothesized that dysbiosis 
induced by HFHFr diet might develop NASH, and eight 
weeks of probiotic supplementation only managed to 
reduce the steatosis, resulting in the ‘Borderline’ result 
in our probiotic group’s NAS Score. We thought that our 
probiotic supplementation duration was not long enough 
to decrease the inflammatory process, as shown in other 
studies that supplied probiotics for a longer period.19 
 In addition, our study discovered that although 
insignificant, probiotic supplementation can decrease 
liver fibrosis. Another study also found that probiotic 
improved liver histology, reduced liver fat, decreased 
serum ALT, and reduced liver fibrosis.9 Furthermore, 
another research found that probiotics supplementation 
also decreased the number of proinflammatory cytokines 
that also had a role in fibrosis.(22) We suggested that in 
this study, a significant decrease of NASH and fibrosis 
were mediated by this mechanism. 
 Interestingly, our study did not find any significant 
weight increase after the HFHFr diet. This finding was 
different from another study, as the samples were able to 
have a significant weight gain in the same amount of 
time.14 We thought that the main trigger for liver damage 
(and resolution) in our samples was mainly caused by 
dysbiosis. Bacterial overgrowth and increased 
translocation of bacteria to the portal and systemic 
circulation, increased lipopolysaccharide (LPS) levels, 
increased endotoxin, and activation of proinflammatory 
signals (TNF-α and IL-6) are seen in various chronic liver 
diseases, including NAFLD.23 Probiotics 
supplementation improved gut mucosa permeability, as 
showed by increased expression of occluding and 
claudin-1 expression as vital markers of tight-junction 
integrity.24 
 There were limitations of this study. The rats were fed 
ad libitum, so there were no data regarding daily/mean 
calorie intake for each group. Measurement of metabolic 
and inflammatory markers, as well as gut microbiota on 
each rat was not done in this study.  We suggested a 
standardized calculation of dietary intake in each rat for 
better understanding the food dose in each group. For 
better understanding of the pathophysiological process, 
we advised in future studies to include the measurement 
of gut microbiota and other related biomarkers. 
 
Table 1. NAFLD Activity Score (NAS) Scoring System 
Item  Score Extent 
 NAS Components 





5 – 33% 
>33 – 66% 
> 66% 





<2 foci / 200x 
2 – 4 foci / 200x 
>4 foci / 200x 




Few balloon cells 
Prominent ballooning 
 
 Fibrosis Stage (Evaluated separately from NAS) 






Perisinusoidal or Periportal 




Table 2. Anthropometrics Characteristic of subjects 
Group Baseline Length Pre-Test Weight Post-Test Weight p 
 Mean ± SD  
C (n = 7) 15.65 ± 0.18 146.00 ± 37.60 169.29 ± 37.46 0.128* 
NP (n = 7) 15.20 ± 0.22 134.29 ± 18.62 141.00 ± 14.92 0.203* 
P(n = 7) 16.00 ± 1.00 118.43 ± 2.23 123.29 ± 11.57 0.203* 












Journal of Biomedicine and Translational Research, 7 (2) 2021, 69-73  
CONCLUSION 
 In conclusion, eight weeks of probiotic 
supplementation reduced NAFLD incidence and 
decreased NAS score in Sprague-Dawley rats induced 
by the HFHFr diet. The results of this study are expected 
to provide new insights for alternative medical treatment 
for patients with NAFLD. However, it is necessary to do 
further research on humans as subjects, with a longer 
probiotics supplementation time for more significant 
results, and consider the probiotics choice. 
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Figure 1. Liver histopathological slides from each group 
(H.E. stained, 200x 
C = Control, NP = Non-Probiotic, P = Probiotic, Red 
Arrow = Inflammatory cell infiltration, Blue Arrow = 
Steatosis, Yellow Arrow = Ballooning) 
 
Table 3. Steatosis Grade Interpretation According to Group 
 
Steatosis Grade Interpretation P 
Not NAFL NAFL  
Group C 7 0  
NP 0 7 0.001* 
P 7 0 
*Fisher’s Exact Test 
 
Table 4. NAS Score Interpretation According to Group 
 
NAS Score Interpretation P 
Not NASH Borderline NASH  
Group C 7 0 0  
NP 0 0 7 0.001* 
P 0 7 0 
*Fisher’s Exact Test 
 
Table 5. Fibrosis Stage According to Group 
 
Fibrosis Stage P 
Stage 1 Stage 2  
Group C 7 0  
NP 6 1 0.500* 
P 7 0 
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